Rosacea Market Size (2024 - 2029)

Rosacea Market Analysis

The Rosacea Market size is estimated at USD 2.09 billion in 2024, and is expected to reach USD 3.19 billion by 2029, growing at a CAGR of 8.74% during the forecast period (2024-2029).

COVID-19 had a significant impact on the growth of the market during the pandemic period. This is mainly due to the worsening of the rosacea condition due to the COVID-19 protection kits.
For instance, according to the article published in February 2021, a survey conducted by Galderma suggested that the pandemic may impact rosacea patients by worsening of signs and symptoms related to mask-wearing, and there were reduced healthcare professional consultations. Thus, the demand for rosacea treatment due to the COVID-19 outbreak contributed to the market's growth during the pandemic period. However, the pandemic has subsided, so the studied market is expected to grow generally during the forecast period.

The growth of the market is attributed to factors such as the increasing prevalence of rosacea among the global population. For instance, the article published by the International Journal of Dermatology in December 2021 mentioned that 2.1% of the survey participants had rosacea. The prevalence of rosacea increased significantly with age. The report also mentioned that Rosacea is a common skin condition most prevalent above the age of 65.

Moreover, according to World Health Organization (WHO) data published in October 2021, it is estimated that 1 in 6 people worldwide will be aged 60 years or over, in seven years. The share of the population aged 60 years and over will increase to 1.4 billion. The world's population of people aged 60 years and older will double (2.1 billion) in 27 years. The number of persons aged 80 or older is expected to triple in 27 years to reach 426 million. Thus, the rising geriatric population worldwide is also expected to boost the growth of the rosacea treatment market.

Moreover, the rising developments by major market players are also expected to boost market growth. For instance, in June 2021, Sol-Gel Technologies and Galderma announced the signing of two exclusive five-year license agreements for the commercialisation of Epsolay and Twyneo in the United States.

Therefore, with rising prevalence, the awareness among physicians and societies has also increased, further driving the demand for this market. However, the presence of generic drugs to curb the related symptoms hinders the growth of the rosacea market.

Rosacea Industry Segmentation

As per the scope of the market, rosacea is a condition diagnosed by symptoms, such as facial flushing, coarseness of the skin, and an inflammatory papulopustular eruption resembling acne. The rosacea market is segmented by drug class (antibiotics, alpha agonists, retinoids, corticosteroids, immunosuppressants, and other drug classes), mode of administration (topical and oral), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD) for the above segments.